174 related articles for article (PubMed ID: 24742627)
1. Extra-prostatic transgene-associated neoplastic lesions in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice.
Berman-Booty LD; Thomas-Ahner JM; Bolon B; Oglesbee MJ; Clinton SK; Kulp SK; Chen CS; La Perle KM
Toxicol Pathol; 2015 Feb; 43(2):186-97. PubMed ID: 24742627
[TBL] [Abstract][Full Text] [Related]
2. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer.
Chiaverotti T; Couto SS; Donjacour A; Mao JH; Nagase H; Cardiff RD; Cunha GR; Balmain A
Am J Pathol; 2008 Jan; 172(1):236-46. PubMed ID: 18156212
[TBL] [Abstract][Full Text] [Related]
3. Malignancy arising in seminal vesicles in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Yeh IT; Reddick RL; Kumar AP
Prostate; 2009 May; 69(7):755-60. PubMed ID: 19170049
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.
Wu GJ; Fu P; Chiang CF; Huss WJ; Greenberg NM; Wu MW
J Urol; 2005 May; 173(5):1778-83. PubMed ID: 15821586
[TBL] [Abstract][Full Text] [Related]
5. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
6. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
[TBL] [Abstract][Full Text] [Related]
7. Deletion of p21/Cdkn1a confers protective effect against prostate tumorigenesis in transgenic adenocarcinoma of the mouse prostate model.
Jain AK; Raina K; Agarwal R
Cell Cycle; 2013 May; 12(10):1598-604. PubMed ID: 23624841
[TBL] [Abstract][Full Text] [Related]
8. A null-mutation in the Znt7 gene accelerates prostate tumor formation in a transgenic adenocarcinoma mouse prostate model.
Tepaamorndech S; Huang L; Kirschke CP
Cancer Lett; 2011 Sep; 308(1):33-42. PubMed ID: 21621325
[TBL] [Abstract][Full Text] [Related]
9. Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers.
Mauri G; Jachetti E; Comuzzi B; Dugo M; Arioli I; Miotti S; Sangaletti S; Di Carlo E; Tripodo C; Colombo MP
Oncotarget; 2016 Jan; 7(4):3905-20. PubMed ID: 26700622
[TBL] [Abstract][Full Text] [Related]
10. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
Foster BA; Gingrich JR; Kwon ED; Madias C; Greenberg NM
Cancer Res; 1997 Aug; 57(16):3325-30. PubMed ID: 9269988
[TBL] [Abstract][Full Text] [Related]
11. Expression level and DNA methylation status of glutathione-S-transferase genes in normal murine prostate and TRAMP tumors.
Mavis CK; Morey Kinney SR; Foster BA; Karpf AR
Prostate; 2009 Sep; 69(12):1312-24. PubMed ID: 19444856
[TBL] [Abstract][Full Text] [Related]
12. Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model.
Schmittgen TD; Zakrajsek BA; Hill RE; Liu Q; Reeves JJ; Axford PD; Singer MJ; Reed MW
Prostate; 2003 Jun; 55(4):308-16. PubMed ID: 12712410
[TBL] [Abstract][Full Text] [Related]
13. Gene expression signatures associated with suppression of TRAMP prostate carcinogenesis by a kavalactone-rich Kava fraction.
Tang SN; Zhang J; Jiang P; Datta P; Leitzman P; O'Sullivan MG; Jiang C; Xing C; Lü J
Mol Carcinog; 2016 Dec; 55(12):2291-2303. PubMed ID: 26840761
[TBL] [Abstract][Full Text] [Related]
14. Androgen-independent prostate cancer progression in the TRAMP model.
Gingrich JR; Barrios RJ; Kattan MW; Nahm HS; Finegold MJ; Greenberg NM
Cancer Res; 1997 Nov; 57(21):4687-91. PubMed ID: 9354422
[TBL] [Abstract][Full Text] [Related]
15. Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes.
Peek EM; Song W; Zhang H; Huang J; Chin AI
Prostate; 2015 Apr; 75(5):463-73. PubMed ID: 25597486
[TBL] [Abstract][Full Text] [Related]
16. Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice.
Chung AC; Zhou S; Liao L; Tien JC; Greenberg NM; Xu J
Cancer Res; 2007 Jun; 67(12):5965-75. PubMed ID: 17575167
[TBL] [Abstract][Full Text] [Related]
17. Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model.
Huss WJ; Gray DR; Tavakoli K; Marmillion ME; Durham LE; Johnson MA; Greenberg NM; Smith GJ
Neoplasia; 2007 Nov; 9(11):938-50. PubMed ID: 18030362
[TBL] [Abstract][Full Text] [Related]
18. Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice.
Kalin TV; Wang IC; Ackerson TJ; Major ML; Detrisac CJ; Kalinichenko VV; Lyubimov A; Costa RH
Cancer Res; 2006 Feb; 66(3):1712-20. PubMed ID: 16452231
[TBL] [Abstract][Full Text] [Related]
19. Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model.
Pu H; Collazo J; Jones E; Gayheart D; Sakamoto S; Vogt A; Mitchell B; Kyprianou N
Cancer Res; 2009 Sep; 69(18):7366-74. PubMed ID: 19738062
[TBL] [Abstract][Full Text] [Related]
20. Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axis but does not reduce tumor progression.
Anzo M; Cobb LJ; Hwang DL; Mehta H; Said JW; Yakar S; LeRoith D; Cohen P
Cancer Res; 2008 May; 68(9):3342-9. PubMed ID: 18451161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]